Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection
Advanced NanoBiomed Research · 2025-08 · 5 (8)
DOI: 10.1002/anbr.202400214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced NanoBiomed Research, online erschienen am 27.06.2025. Verfasst von Geetha Jyothi Vaskuri und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Breakthrough infections in vaccinated population and continuous emergence of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) variants make it imperative to develop more efficacious medical countermeasures. Previously, an anti‐SARS‐CoV‐2 nanobody, Nanosota‐3A, that neutralizes the infection of live Omicron BA.1 with picomolar potency, is identified. Herein, Nanosota‐3A is fused with the crystallizable fragment (Fc) domain of human IgG1 that contains M252Y/S254T/T256E (YTE) substitutions, named Nanosota‐3A‐Fc‐YTE. Compared to Nanosota‐3A‐Fc, Nanosota‐3A‐Fc‐YTE exhibits identical binding to the SARS‐CoV‐2 spike protein yet displays eightfold higher binding affinity for human neonatal Fc receptor (hFcRn) at pH 6.0. In hFcRn transgenic mice, the half‐life of Nanosota‐3A‐Fc and Nanosota‐3A‐Fc‐YTE is 5.1 days and 24.8 days, respectively. The mice are challenged with intranasal exposure of Omicron B.1.1.529 virus 55 days after a single dose of Nanosota‐3A fusions (20 mg kg −1 ) is administered. Compared to the untreated controls, the lung viral titers in mice receiving Nanosota‐3A‐Fc‐YTE are reduced by 104.7‐fold ( p = 0.007) with 50% of the mice free of detectable virus. By contrast, Nanosota‐3A‐Fc‐treated mice show only 3.5‐fold reduction in the viral titers ( p = 0.41). The durable protection conferred by a single dose of Nanosota‐3A‐Fc‐YTE administered nearly 2 months prior to the virus exposure demonstrates the promise of long‐circulating nanobodies as powerful prophylactics against SARS‐CoV‐2.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA.
- Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA.
- Department of Pharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN 38163, USA; Regional Biocontainment Laboratory, University of Tennessee Health Science Center, Memphis, TN 38163, USA; De…
Förderung
- NIAID NIH HHS
- National Institute of Allergy and Infectious Diseases
Zitieren
APA
Vaskuri, G. J., Ye, G., Bu, F., Yang, D., Jonsson, C. B., Turner-Hubbard, H., Winecke, S., Mendoza, A., Li, F., & Tan, C. (2025). Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection. Advanced NanoBiomed Research, 5(8). https://doi.org/10.1002/anbr.202400214
Vancouver
Vaskuri GJ, Ye G, Bu F, Yang D, Jonsson CB, Turner-Hubbard H, et al. Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection. Advanced NanoBiomed Research. 2025;5(8). doi:10.1002/anbr.202400214
BibTeX
@article{Vaskuri2025,
author = {Vaskuri, Geetha Jyothi and Ye, Gang and Bu, Fan and Yang, Dong and Jonsson, Colleen B and Turner-Hubbard, Hailey and Winecke, Sydney and Mendoza, Alise and Li, Fang and Tan, Chalet},
title = {Long‐Circulating Nanobody Confers Durable Prophylaxis against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Infection},
journal = {Advanced NanoBiomed Research},
year = {2025},
volume = {5},
number = {8},
doi = {10.1002/anbr.202400214}
}
EUVIMED